Assessment of optimal protein dosage for maintaining and synthesizing muscle volume in inpatients with type 2 diabetes: Randomized Controlled Trial

Assessment of optimal protein dosage for maintaining and synthesizing muscle volume in inpatients with type 2 diabetes: Randomized Controlled Trial - The optimal protein intake for patients in type 2 diabetes educational admission

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047180

Enrollment

Registered

2022-03-16

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with type 2 diabetes

Interventions

protein supplementation group normal diet group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: .

Exclusion criteria

Exclusion criteria: .

Design outcomes

Primary

Measure	Time frame
Muscle volume increasing ratio between the two groups: High dose group; protein dose of 1.3 g / ideal body weight (kg) or more vs. Low dose group; protein dose of less than 1.3 g / ideal body weight (kg)	—

Secondary

Measure	Time frame
Divide the protein dose into ~ 0.9 / 1.0 / 1.1 / 1.2 / 1.3 / 1.4 / 1.5g / kg ~ to determine at which dose muscle volume changes from loss to increase.	—

Countries

Japan

Contacts

Public ContactChinatsu Yamagami

Kyushu Nutrition Welfare University Nutrition

kishitani.hatahata@gmail.com+81-93-561-2136

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026